Moderna (NASDAQ:MRNA) shares dropped on Wednesday after the latest efficacy data for its newly ... GSK (GSK) and Pfizer (PFE) currently dominate the market for RSV vaccines after the FDA approved ...

Patent Trial and Appeal Board (PTAB) docket entries indicate that the PTAB has invalidated all challenged claims of Moderna’s ...

The FDA instead reviewed data that Pfizer and Moderna had collected from clinical studies of the safety and efficacy of earlier iterations of the shot, which had been targeted at the original Omicron ...

Moderna said Friday that the European Patent Office has upheld the validity of one of its key patents, a victory in a continuing dispute with Pfizer and BioNTech over rival COVID-19 vaccines.

Before that, Moderna (NYSE: MRNA) had filed a patent infringement lawsuit against Pfizer and BioNTech in federal court in Massachusetts in 2022. That lawsuit has been on hold waiting for the ...

The rivalry between Moderna and Pfizer/BioNTech in commercialising their COVID-19 vaccines has now spilled over into the courts, in the form of a patent infringement lawsuit.

Pfizer and partner BioNTech have launched a countersuit against Moderna in a patent dispute centring on their mRNA-based vaccines for COVID-19. Moderna fired the first volley back in August ...

Freshfields has won a Düsseldorf regional court patent dispute on behalf of client Moderna against German COVID-19 vaccine inventors BioNTech and Pfizer. BioNTech, represented by Taylor Wessing ...

In a statement, the court in the city of Duesseldorf said that Pfizer and BioNTech would have to provide information on earnings derived from the use of the patent and that they owe Moderna ...

It wasn't all positive for Pfizer and BioNTech on the patent front this week, though. In Germany, the Düsseldorf Regional Court ruled for Moderna in a case that also dates back to 2022. The court ...